Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder

Psychiatry Res. 2012 Nov 30;200(1):63-5. doi: 10.1016/j.psychres.2012.06.002. Epub 2012 Jun 22.


In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use*
  • Catechol O-Methyltransferase / genetics
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Duloxetine Hydrochloride
  • Female
  • Humans
  • Male
  • Models, Genetic*
  • Norepinephrine Plasma Membrane Transport Proteins / genetics
  • Polymorphism, Single Nucleotide
  • Receptor, Serotonin, 5-HT1A / genetics
  • Surveys and Questionnaires
  • Thiophenes / therapeutic use*
  • Treatment Outcome


  • Antidepressive Agents
  • Norepinephrine Plasma Membrane Transport Proteins
  • SLC6A2 protein, human
  • Thiophenes
  • Receptor, Serotonin, 5-HT1A
  • Duloxetine Hydrochloride
  • Catechol O-Methyltransferase